Results 81 to 90 of about 27,503 (257)

Dipeptidyl Peptidase-4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination. [PDF]

J Dermatol
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Lee J, Bae JH, Hahn S.
europepmc   +2 more sources

Perioperative glycaemic profiles in Aboriginal and Torres Strait Islander people with diabetes mellitus

Diabetic Medicine, EarlyView.
This large multicentre retrospective cohort study in Australia revealed that despite being younger and having greater preoperative comorbidity and higher HbA1c levels, Aboriginal and Torres Strait Islander adults with diabetes mellitus demonstrate higher rates of perioperative hypoglycaemia, but otherwise comparable markers of glycaemic variability and
Katerina Flabouris, Odette R. Pearson, Kim Morey, Suzanne M. Edwards, David R. Jesudason, Chinmay S. Marathe   +5 more
wiley   +1 more source

Sulphostin-inspired N-phosphonopiperidones as selective covalent DPP8 and DPP9 inhibitors

Nature Communications
Covalent chemical probes and drugs combine unique pharmacologic properties with the availability of straightforward compound profiling technologies via chemoproteomic platforms.
Leonard Sewald, Werner W. A. Tabak, Lorenz Fehr, Samuel Zolg, Maja Najdzion, Carlo J. A. Verhoef, David Podlesainski, Ruth Geiss-Friedlander, Alfred Lammens, Farnusch Kaschani, Doris Hellerschmied, Robert Huber, Markus Kaiser   +12 more
doaj   +1 more source

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease

Diabetes, Metabolic Syndrome and Obesity, 2020
Lin Chen,1,* Xiujuan Zhang,2,* Li Zhang,3 Dongmei Zheng2 1Department of Breast and Thyroid Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People’s Republic of China; 2Department of ...
Chen L, Zhang X, Zhang L, Zheng D
doaj  

Health economic evaluation of dipeptidyl peptidase-4 inhibitors

Indian Journal of Endocrinology and Metabolism, 2011
Sir, The predicted loss of national income from diabetes in India is 336.6 billion International Dollars.[1] Furthermore, studies have demonstrated that the prevalence of diabetes in India is rising with the progression of time.[2] Therefore, this financial burden is bound to increase.
openaire   +3 more sources

Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Care home admission often reflects frailty and limited life expectancy, potentially altering the benefit‐harm balance of glucose‐lowering drug (GLD) treatment for type 2 diabetes (T2D). Real‐world data on treatment patterns in this setting remain limited. We examined GLD use for T2D among Danish care home residents.
Hanin Harbi, Reimar W. Thomsen, Carina Lundby, Jacob Volmer Stidsen, Kurt Højlund, Jesper Ryg, Mette Reilev, Anton Pottegård   +7 more
wiley   +1 more source

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions

Indian Journal of Endocrinology and Metabolism, 2014
The pharmacological actions of the glucagon-like peptide-1 receptor agonists (GLP-1RA) are largely predictable as they interact directly with GLP-1 receptors on beta cells to mediate their glucose lowering effects by increasing GLP-1 in pharmacological range and not at all dependent upon endogenous GLP-1 secretion. The mechanism of action of dipeptidyl
openaire   +3 more sources

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 ...
Jun Sung Moon, Kyung Ah Han, Dong‐Lim Kim, Sang Yong Kim, Soo‐Kyung Kim, Bon Jeong Ku, Woo Je Lee, Tae Keun Oh, Ji A Seo, Sang‐Ah Chang, Moon‐Kyu Lee, Kyu Jeung Ahn, Chul Sik Kim, Tae Nyun Kim, Bong‐Soo Cha   +14 more
wiley   +1 more source

Alogliptin benzoate for management of type 2 diabetes

Vascular Health and Risk Management, 2015
Yoshifumi Saisho Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Abstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress ...
Saisho Y
doaj  

Sensor‐Detected Hypoglycaemia Is Associated With Inflammatory Protein and Immune Cell Alterations in People With Diabetes: Findings From the Hypo‐METRICS Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Experimental hypoglycaemia induces a persistent inflammatory response. We investigated whether real‐life sensor‐detected hypoglycaemia (SDH) is associated with immune parameters in people with Type 1 and Type 2 diabetes and explored potential differences between the groups.
Mandala Ajie, Namam Ali, Marijn S. Hendriksz, Patrick Divilly, Marloes J. Rietveld, Evertine J. Abbink, Pratik Choudhary, Julie Maria Bøggild Brøsen, Ulrik Pedersen‐Bjergaard, Rory J. McCrimmon, Mark Evans, Julia K. Mader, Bastiaan E. de Galan, Rinke Stienstra, Cees J. Tack, on behalf of the Hypo‐RESOLVE Consortium   +15 more
wiley   +1 more source